Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 78.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,642 shares of the company’s stock after buying an additional 44,986 shares during the quarter. Squarepoint Ops LLC’s holdings in Tarsus Pharmaceuticals were worth $4,158,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after acquiring an additional 339 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after purchasing an additional 2,782 shares during the period. Quarry LP increased its holdings in shares of Tarsus Pharmaceuticals by 20.0% in the 1st quarter. Quarry LP now owns 3,599 shares of the company’s stock valued at $185,000 after purchasing an additional 599 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the first quarter valued at about $189,000. Finally, Allianz Asset Management GmbH purchased a new stake in Tarsus Pharmaceuticals during the second quarter worth about $227,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total value of $332,220.00. Following the completion of the transaction, the chief executive officer owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. The trade was a 0.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 8.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TARS. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $51.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, November 6th. Mizuho began coverage on Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective for the company. Wall Street Zen raised Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Zacks Research raised Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Finally, Guggenheim lifted their price target on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $79.86.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $80.48 on Tuesday. The stock’s 50 day moving average price is $74.41 and its 200 day moving average price is $57.29. The firm has a market cap of $3.42 billion, a P/E ratio of -39.84 and a beta of 0.74. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.The company had revenue of $118.70 million during the quarter, compared to the consensus estimate of $114.22 million. On average, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.